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TriazolothiadiazineAbstract Pathogenic microbes have mutated and developed resistance to the latest range of antibi-
otics, which has kept synthetic chemist hunting for better and least toxic antimicrobial agents.
Cyclocondensation of substituted anilines with 3-phenyl-2-propenoic acid yielded Phenyl-(substitu
ted)-quinolin-2-one derivatives (1a–1t). In the next step phenylquinolin-2-one acetic acid derivatives
(2a–2t) were prepared by the treatment of (1a–1t) with chloroacetic acid. Further (2a–2t) derivatives
were reacted with thiocarbohydrazide to obtain a series of 4-amino-5-sulfanyl-4,5-dihydro-1,2,4-tria
zolo-4-pheny-(substituted)-quinolin-2-one derivatives (3a–3t). Then condensation of (3a–3t) with
phenacyl bromide provided series of fused heterocyclic derivatives of 4-phenyl-1-({6-phenyl-7H-[1
,2,4]triazolo[3,4-b][1,3,4]thiadiazin-3-yl}methyl)-(substituted)-1,2-dihydro quinolin-2-one (4a–4t).
Structures of these newly synthesized derivatives were established by elemental analysis, FT-IR,
1H NMR and Mass spectroscopy. Final derivatives (4a–4t) were screened for their in vitro antibac-
terial and antifungal activities against the standard drugs Ampicillin and Fluconazole respectively.
The compounds 4d, 4g and 4j showed potent activity against all the studied microbes. Particularly
compounds substituted with halogen groups at para position of phenylquinoline ring exhibited
signiﬁcant antimicrobial activity against studied microbes.
ª 2015 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rapid increase in pathogenic fungi and bacteria that are multi
resistant to antibiotics has become major threat in treatment
of infectious diseases. Heterocyclic compounds having 1,2,4-
triazolo ring system substituted with nitrogen and sulfur exhibit
a wide range of biological activities such as antibacterialine bear-
2 S. Ghosh et al.(Guzeldemirci and Kucukbasmac, 2010; Karegoudar et al.,
2008), antifungal (Fang et al., 2010; Banday and Rauf, 2009),
antitubercular (Bhat et al., 2004) properties. Also a number of
Quinoline derivatives have been well known to possess a variety
of pharmacological activities like antibacterial (Zitouni et al.,
2005), antifungal (Purohit et al., 2011) and anti-inﬂammatory
(Tozkoparan et al., 2000; Amir et al., 2008; Chen et al., 2006;
Abdel-Megeed et al., 2009). Literature survey reveals that hete-
rocyclic compounds containing halogen atoms have attracted
attention due to ability of halogens to act as hydroxy mimic
agent. So substitution of hydrogen by halogens and other
substituents plays an important role in designing new pharma-
cophores for biological studies. Various compounds containing
1,2,4-Triazolo nucleus are well known as powerful antibacterial
(Varvaresou et al., 2000), antifungal and antimycobacterial
agents (Sridharaa et al., 2010; Karegoudar et al., 2008).
Moreover the use of heterocyclic compounds containing
1,3,4-Thiadiazoles and 1,3,4-Thiadiazines is widely known
due to their therapeutic effects against pathological conditions
such as pain, inﬂammation, and hypertension (Ahmad et al.,
2012; Clerici et al., 2001). The synthesis of heterocyclic rings
containing both 1, 2, 4-Triazolo nucleus and 1, 3, 4-
Thiadiazine ring has attracted attention due to their antimicro-
bial (Goksen et al., 2007), analgesic (Turan-Zitouni et al., 1999),
antiviral and anti-inﬂammatory properties (Isloor et al., 2009;
Abadi et al., 2005). The problem of drug resistance of the patho-
genic strains of microbes to the older derivatives of triazoles is a
well-known fact for the researchers. Therefore it was planned to
synthesize a new series of 4-phenyl-1-({6-phenyl-7H-[1,2,4]tria
zolo[3,4-b][1,3,4]thiadiazin-3-yl}methyl)-(substituted)-1,2-dihy
droquinolin-2-one (4a–4t) derivatives by linking (substituted)-
4-phenylquinolin-2(1H)-one with 1,2,4-triazolo[3,4-b][1,3,4]thi
adiazine moiety (Fig. 1) and to evaluate their in vitro antimicro-
bial activity.
2. Materials and methods
2.1. General
The entire chemicals required for the synthesis and other
experimental work were purchased from Merck, SigmaFigure 1 General structure of
Please cite this article in press as: Ghosh, S. et al., Synthesis, characterization and an
ing substituted phenylquinolin-2-one moiety. Arabian Journal of Chemistry (2015),Aldrich and Rankem chemical company. Melting points of
all synthesized compounds were determined in open capillaries
by Temp Star apparatus and are uncorrected. The purity of the
compounds was routinely checked in each step by TLC using
Silica Gel 60G and the developed plates were visualized by
UV light. Spectroscopic data were recorded by the following
instruments; IR spectra were recorded on FT-IR-8400S,
Schimadzu, Japan, 1H NMR spectra were recorded by
Bruker DRX – 300 MHz FT NMR with low and high
temperature facility (90 C to +80 C) in the solvents
CDCl3. Chemical shifts are reported in parts per million (d)
and signals are described as singlet (s), doublet (d), triplet
(t), quartet (q) and multiplet (m). The Mass spectra were
obtained by Agilent 6520 Q-TOF (ESI-MS) and Elemental
analysis was done by Elemental Analyzer: Vario EL-III.
2.2. Chemistry
In the present work twenty novel derivatives of phenylquino
line-1,2,4-triazolothiadiazines were synthesized, following the
synthetic route given in Scheme 1. The starting material
phenylquinoline-2-one derivatives (1a–1t) for the synthesis of
desired compounds were obtained by cyclocondensation
(Lipson et al., 2000) of Aniline derivatives with 3-phenyl-2-
propenoic acid (Cinnamic acid) in the presence of ethanol,
conc. H2SO4 and Nitrobenzene. In this step conc. H2SO4 acts
as condensing reagent and catalyst to favor forward reaction.
Then the compounds (1a–1t) on the treatment with chloroace-
tic acid in the presence of alkaline medium provided 2-oxophe
nyl-(substituted)-quinolin-1-ylacetic acid derivatives (2a–2t).
In the next step (2a–2t) on heating with thiocarbohydrazide
gave 4-amino-5-sulfanyl-4,5-dihydro-1,2,4-triazol-4-phenyl-
(substituted)-quinolin-2-one (3a–3t) in good yield. Then
cyclization of (3a–3t) with phenacyl bromide in the pres-
ence of anhydrous ethanol provided the desired product
4-phenyl-1-({6-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-
3-yl}methyl)-(substituted)-1,2-dihydroquino line-2-one (4a–4t).
The synthesized compounds were puriﬁed and recrystallized
using ethanol and acetone. The characterization of these
new derivatives was done by their Elemental analysis and
spectroscopic (FT-IR, 1H NMR and MASS) data.ﬁnal synthesized derivatives.
timicrobial evaluation of some novel 1,2,4-triazolo [3,4-b][1,3,4]thiadiazine bear-
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Scheme 1 Synthetic Scheme for 1,2,4-triazolo[3,4-b][1,3,4]thiadiazine bearing substituted phenylquinolin-2-one (4a–4t). Where R=H,
2-Br, 3-Br, 4-Br, 2-Cl, 3-Cl, 4-Cl, 2-F, 3-F, 4-F, 2-NO2, 3-NO2, 4-NO2, 2-CH3, 3-CH3, 4-CH3, 2-OCH3, 3-OCH3, 4-OCH3, 3,4,5-t-OCH3.
Reagents and conditions: (a) C2H5OH, Nitrobenzene, Con. H2SO4, reﬂux, 80 C, 4 h; (b) chloroacetic acid, NaHCO3, water, CuO, reﬂux,
80 C, 5 h; (c) thiocarbohydrazide, D, 2 h; (d) phenacyl bromide, anhydrous ethanol, NH4OH, 50 C, 6 h.
Novel 1,2,4-triazolo[3,4-b][1,3,4]thiadiazine bearing substituted phenylquinolin-2-one moiety 32.3. General procedure for the synthesis of Phenyl-(substituted)-
quinolin-2-one derivatives (1a–1t)
Equimolar quantity of aniline derivatives (0.1 mol) and 3-
phenyl-2-propenoic acid (14.8 g, 0.1 mol) were reﬂuxed for
4 h using 20 ml of ethanol in the presence of 2–4 drops of conc.
Sulfuric acid and 2–3 drops of nitrobenzene. After reﬂuxing
the resulting product was kept at room temperature and then
ﬁltered. The ﬁltered product was left for overnight to dry in
hot air oven by maintaining temperature 40 C and then the
product was recrystallized from ethanol.
2.4. General procedure for the synthesis of 2-oxo-4-phenyl-
(substituted)- quinolin-acetic acid derivatives (2a–2t)
In this step the compounds (1a–1t) 0.01 mol reﬂuxed with
Chloroacetic acid (0.94 g, 0.01 mol) in the presence of
NaHCO3, CuO and water for 2 h. The resulting solution was
ﬁltered and allowed to cool at room temperature. To the ﬁl-
trate dilute HCl was added. The solid thus separated out was
dried and recrystallized from ethanol.
2.5. General procedure for the synthesis of 4-amino-5-sulfanyl-
4,5-dihydro-1,2,4-triazolo-4-phenyl-(substituted)- quinolin-2-
one (3a–3t)
Mixture of 2a–2t (0.03 mol) and thiocarbohydrazide (3.18 g,
0.03 mol) was heated till all the contents melted. A homoge-
nous reaction mixture was obtained during reaction process.
Then the product was treated with dilute sodium carbonate
solution. The white solid separated out was ﬁltered, washed
twice with cold water. Then the product was recrystallized
from Acetone.Please cite this article in press as: Ghosh, S. et al., Synthesis, characterization and ant
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phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-3-yl}-
methyl)-(substituted)-1,2-dihydroquinolin-2-one (4a–4t)
The synthesized compounds 3a–3t (0.003 mol) were reﬂuxed
with Phenacylbromide (0.597 g, 0.003 mol) in the presence of
anhydrous ethanol (30 ml) with continuous stirring for 6 h.
The resulting reaction mixture was allowed to attain room
temperature and was neutralized with 20% NH4OH solution.
The separated precipitate was the ﬁltered and recrystallized
from ethanol to obtain the ﬁnal derivatives (4a–4t).
2.6.1. 4-Phenyl-1-({6-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]
thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one (4a)
White Solid Crystal; IR (KBr, cm1): 3040 (Ar CAH str), 1702
(C‚O str), 1610 (C‚N str), 1577 (C‚C str), 1306 (Ar CAN
str), 650 (CASAC); 1H NMR (CDCl3, 300 MHz): d (ppm):
4.61 (s, 2H, SACH2A), 5.97 (s, 2H, CH2), 6.98 (s, 1H,
CH‚), 7.41–7.42 (m, 2H, ArAH), 7.45 (q, 2H, J= 8.0 Hz,
ArAH), 7.46 (t, 6H, J= 8.0 Hz, ArAH), 7.53 (q, 1H,
ArAH), 7.73–7.75 (m, 3H, ArAH). ESI-MS (m/z) calcd. is
449.5, found 450.5 [M +H]+; anal. calcd. for C26H19N5OS
(449.52): C 69.47, H 4.26, N 15.58; found: C 69.43, H 4.20,
N 15.53.
2.6.2. 8-Bromo-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo[3,4b]
[1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one (4b)
Brown amorphous Solid; IR (KBr, cm1): 3042 (Ar CAH str),
1710 (C‚O str), 1640 (C‚N str), 1550(C‚C str), 1320 (Ar
CAN str), 650 (CASAC), 740 (CABr); 1H NMR (CDCl3,
300 MHz): d (ppm): 4.52 (s, 2H, SACH2A), 5.94 (s, 2H,
CH2), 6.78 (s, 1H, CH‚), 7.21 (t, 1H, J= 7.5 Hz, ArAH),
7.42–7.44 (m, 3H, ArAH), 7.46 (d, 4H, J= 8.0 Hz, ArAH),imicrobial evaluation of some novel 1,2,4-triazolo [3,4-b][1,3,4]thiadiazine bear-
http://dx.doi.org/10.1016/j.arabjc.2015.07.003
4 S. Ghosh et al.7.48 (q, 2H, J= 8.0 Hz, ArAH), 7.75 (q, 3H, ArAH). ESI-MS
(m/z) calcd. is 528.4, found 529.5 [M + H]+; anal. calcd. for
C26H18BrN5OS (528.42): C 59.10, H 3.43, N 13.25; found: C
59.09, H 3.48, N 13.28.
2.6.3. 7-Bromo-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo[3,4b]
[1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one (4c)
Brown amorphous Solid; IR (KBr, cm1): 3041 (Ar CAH str),
1709 (C‚O str), 1632 (C‚N str), 1535 (C‚C str), 1325 (Ar
CAN str), 648 (CASAC), 742 (CABr); 1H NMR (CDCl3,
300 MHz): d (ppm) : 4.53 (s, 2H, SACH2A), 6.05 (s, 2H,
CH2), 7.18 (s, 1H, CH‚), 7.41 (m, 2H, ArAH), 7.46 (t, 4H,
J= 8.0 Hz, ArAH), 7.73 (q, 5H, J= 8.0 Hz, ArAH), 8.08 (d,
2H, J= 8.0 Hz, ArAH). ESI-MS (m/z) calcd. is 528.4, found
529.2 [M+ H]+; anal. calcd. for C26H18BrN5OS (528.42): C
59.10, H 3.43, N 13.25; found: C 59.09, H 3.48, N 13.28.
2.6.4. 6-Bromo-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo[3,4b]
[1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one (4d)
Brown amorphous Solid; IR (KBr, cm1): 3039 (Ar CAH str),
1706 (C‚O str), 1635 (C‚N str), 1539 (C‚C str), 1328 (Ar
CAN str), 647 (CASAC), 744 (CABr); 1H NMR (CDCl3,
300 MHz): d (ppm) : 4.52 (s, 2H, SACH2A), 5.98 (s, 2H,
CH2), 6.78 (s, 1H, CH‚), 7.41–7.45 (m, 2H, ArAH), 7.46 (t,
4H, J= 8.0 Hz, ArAH), 7.47 (q, 3H, J= 8.5 Hz, ArAH),
7.73 (q, 2H, J= 8.0 Hz, ArAH) 8.01 (d, 2H, J = 8.5 Hz,
ArAH). ESI-MS (m/z) calcd. is 528.4, found 529.6
[M +H]+; anal. calcd. for C26H18BrN5OS (528.42): C 59.10,
H 3.43, N 13.25; found: C 59.13, H 3.39, N 13.28.
2.6.5. 8-Chloro-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo[3,4b]
[1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one (4e)
White Solid Crystal; IR (KBr, cm1): 3038 (Ar CAH str), 1700
(C‚O str), 1611 (C‚N str), 1549 (C‚C str), 1338 (Ar CAN
str), 665 (CASAC), 758 (CACl); 1H NMR (CDCl3, 300 MHz):
d (ppm): 4.54 (s, 2H, SACH2A), 6.04 (s, 2H, CH2), 6.78 (s, 1H,
CH‚), 7.19 (t, 1H, J= 7.5 Hz, ArAH), 7.36–7.40 (m, 3H,
ArAH), 7.46 (d, 4H, J= 8.0 Hz, ArAH), 7.48 (q, 2H,
J = 8.5 Hz, ArAH), 7.75 (q, 3H, J = 8.0 Hz, ArAH), ESI-
MS (m/z) calcd. is 483.9, found 484.8 [M +H]+; anal. calcd.
for C26H18ClN5OS (483.97): C 64.52, H 3.75, N 14.47; found:
C 64.51, H 3.77, N 14.43.
2.6.6. 7-Chloro-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo[3,4b]
[1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one (4f)
White Solid Crystal; IR (KBr, cm1): 3035 (Ar CAH str), 1748
(C‚O str), 1608 (C‚N str), 1538 (C‚C str), 1340 (Ar CAN
str), 662 (CASAC), 750 (CACl); 1H NMR (CDCl3, 300 MHz):
d (ppm): 4.53 (s, 2H, SACH2A), 6.02 (s, 2H, CH2), 7.18 (s, 1H,
CH‚), 7.41–7.45 (m, 2H, ArAH), 7.46 (t, 4H, J= 8.0 Hz,
ArAH), 7.73 (q, 5H, J= 8.5 Hz, ArAH), 8.08 (d, 2H,
J= 8.0 Hz, ArAH). ESI-MS (m/z) calcd. is 483.9, found
484. [M + H]+; anal. calcd. for C26H18ClN5OS (483.97): C
64.52, H 3.75, N 14.47; found: C 64.50, H 3.71, N 14.42.
2.6.7. 6-Chloro-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo[3,4b]
[1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one (4g)
White Solid Crystal; IR (KBr, cm1): 3032 (Ar CAH str), 1745
(C‚O str), 1609 (C‚N str), 1530 (C‚C str), 1332 (Ar CAN
str), 668 (CASAC), 755 (CACl); 1H NMR (CDCl3,Please cite this article in press as: Ghosh, S. et al., Synthesis, characterization and an
ing substituted phenylquinolin-2-one moiety. Arabian Journal of Chemistry (2015),300 MHz): d (ppm): 4.52 (s, 2H, SACH2A), 5.98 (s, 2H,
CH2), 6.78 (s, 1H, CH‚), 7.31–7.36 (m, 2H, ArAH), 7.46 (t,
4H, J= 8.0 Hz, ArAH), 7.52 (q, 3H, J = 8.5 Hz, ArAH),
7.73 (q, 2H, J = 2.5 Hz, ArAH), 8.38 (d, 2H, J = 8.5 Hz,
ArAH). ESI-MS (m/z) calcd. is 483.9, found 484.6
[M+ H]+; anal. calcd. for C26H18ClN5OS (483.97): C 64.52,
H 3.75, N 14.47; found: C 64.55, H 3.79, N 14.45.
2.6.8. 8-Fluoro-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo[3,4b]
[1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one (4h)
White ﬂakes of Solid Crystal; IR (KBr, cm1): 3020 (Ar CAH
str), 1720 (C‚O str), 1640 (C‚N str), 1536 (C‚C str), 1322
(Ar CAN str), 645 (CASAC), 747 (CAF); 1H NMR (CDCl3,
300 MHz): d (ppm): 4.56 (s, 2H, SACH2A), 6.05 (s, 2H,
CH2), 6.78 (s, 1H, CH‚), 7.24 (t, 1H, J= 7.5 Hz, ArAH),
7.41–7.43 (m, 3H, ArAH), 7.46 (d, 4H, J= 8.5 Hz, ArAH),
7.48 (q, 2H, J = 8.0 Hz, ArAH), 7.92 (q, 3H, J = 2.5 Hz,
ArAH). ESI-MS (m/z) calcd. is 467.5, found 468.4
[M+ H]+; anal. calcd. for C26H18FN5OS (467.51): C 66.79,
H 3.88, N 14.98; found: C 66.73, H 3.85, N 14.99.2.6.9. 7-Fluoro-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo[3,4b]
[1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one (4i)
White ﬂakes of Solid Crystal; IR (KBr, cm1): 3019 (Ar CAH
str), 1721 (C‚O str), 1642 (C‚N str), 1537 (C‚C str), 1326
(Ar CAN str), 649 (CASAC), 749 (CAF); 1H NMR (CDCl3,
300 MHz): d (ppm): 4.55 (s, 2H, SACH2A), 6.05 (s, 2H, CH2),
7.18 (s, 1H, CH‚), 7.41–7.43 (m, 2H,ArAH), 7.48 (t, 4H,
J= 2.5 Hz, ArAH), 7.89 (q, 5H, J = 8.0 Hz, ArAH), 8.08 (d,
2H, J = 8.0 Hz, ArAH). ESI-MS (m/z) calcd. is 467.5, found
468.6 [M + H]+]+; anal. calcd. for C26H18FN5OS (467.51): C
66.79, H 3.88, N 14.98; found: C 66.73, H 3.84, N 14.96.2.6.10. 6-Fluoro-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo
[3,4b][1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one
(4j)
White ﬂakes of Solid Crystal; IR (KBr, cm1): 3017 (Ar CAH
str), 1730 (C‚O str), 1643 (C‚N str), 1539 (C‚C str), 1318
(Ar CAN str), 667 (CASAC), 756 (CAF); 1H NMR (CDCl3,
300 MHz): d (ppm): 4.58(s, 2H, SACH2A), 5.98 (s, 2H,
CH2), 6.80 (s, 1H, CH‚), 7.44–7.45 (m, 2H, ArAH), 7.48 (t,
4H, J= 2.5 Hz, ArAH), 7.52 (q, 3H, J = 8.0 Hz, ArAH),
7.78 (q, 2H, J = 8.0 Hz, ArAH), 8.38 (d, 2H, J = 8.0 Hz,
ArAH). ESI-MS (m/z) calcd. is 467.5, found 468.4
[M+ H]+; anal. calcd. for C26H18FN5OS (467.51): C 66.79,
H 3.88, N 14.98; found: C 66.77, H 3.84, N 14.99.2.6.11. 8-Nitro-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo[3,4b]
[1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one (4k)
Yellow ﬂakes of Solid Crystal; IR (KBr, cm1): 3045 (Ar CAH
str), 1735 (C‚O str), 1620 (C‚N str), 1540 (C‚C str), 1300,
890 (Ar CAN str), 670 (CASAC); 1H NMR (CDCl3,
300 MHz): 4.41 (s, 2H, SACH2A), 5.89 (s, 2H, CH2), 6.78 (s,
2H, CH‚), 7.43–7.45 (m, 2H, ArAH), 7.46 (t, 4H,
J= 8.0 Hz, ArAH), 7.48 (q, 2H, J = 8.0 Hz ArAH), 7.58 (t,
1H, ArAH), 8.13 (q, 3H, ArAH). ESI-MS (m/z) calcd. is
494.5, found 495.3 [M + H]+; anal. calcd. for C26H18N6O3S
(494.52): C 63.15, H 3.67, N 16.99; found: C 63.19, H 3.63,
N 16.98.timicrobial evaluation of some novel 1,2,4-triazolo [3,4-b][1,3,4]thiadiazine bear-
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Novel 1,2,4-triazolo[3,4-b][1,3,4]thiadiazine bearing substituted phenylquinolin-2-one moiety 52.6.12. 7-Nitro-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo[3,4b]
[1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one (4l)
Yellow ﬂakes of Solid Crystal; IR (KBr, cm1): 3046 (Ar CAH
str), 1731 (C‚O str), 1622 (C‚N str), 1541 (C‚C str), 1303,
882 (Ar CAN str), 672 (CASAC); 1H NMR (CDCl3,
300 MHz): 4.42 (s, 2H, SACH2A), 6.26 (s, 2H, CH2), 7.18 (s,
1H, CH‚), 7.30 (d, 2H, J= 7.5 Hz, ArAH), 7.45–7.46 (t,
5H, J= 8.0 Hz, ArAH), 7.49 (q, 2H, J = 8.0 Hz, ArAH),
8.01 (q, 3H, J = 7.5 Hz, ArAH), 8.75 (d, 1H, J = 8.5 Hz,
ArAH). ESI-MS (m/z) calcd. is 494.5, found 495.6
[M + H]+; anal. calcd. for C26H18N6O3S (494.52): C 63.15,
H 3.67, N 16.99; found: C 63.12, H 3.65, N 16.95.
2.6.13. 6-Nitro-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo[3,4b]
[1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one (4m)
Yellow ﬂakes of Solid Crystal; IR (KBr, cm1): 3040 (Ar CAH
str), 1732 (C‚O str), 1624 (C‚N str), 1543 (C‚C str), 1306,
875 (Ar CAN str), 673 (CASAC); 1H NMR (CDCl3,
300 MHz): 4.42 (s, 2H, SACH2A), 6.21 (s, 2H, CH2), 6.80(s,
1H, CH‚), 7.43–7.45 (m, 2H, ArAH), 7.46 (t, 4H,
J= 8.0 Hz, ArAH), 7.49 (q, 2H, J = 8.0 Hz, ArAH), 7.73
(q, 2H, ArAH), 8.05 (d, 2H, J = 8.5 Hz, ArAH), 9.04 (d,
1H, J = 8.0 Hz, ArAH). ESI-MS (m/z) calcd. is 494.5, found
495.5 [M + H]+; anal. calcd. for C26H18N6O3S (494.52): C
63.15, H 3.67, N 16.99; found: C 63.10, H 3.69, N 16.95.
2.6.14. 8-Methyl-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo
[3,4b][1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one
(4n)
White Solid Crystal; IR (KBr, cm1): 3010 (Ar CAH str), 2895
(Aliphatic CAH str), 1704 (C‚O str), 1605 (C‚N str), 1560
(C‚C str), 1304 (Ar CAN str), 662 (CASAC); 1H NMR
(CDCl3, 300 MHz): d (ppm): 2.61 (s,3H,CH3), 4.53 (s, 2H,
SACH2A), 5.95 (s, 2H, CH2), 6.78 (s, 1H, CH‚), 7.29–7.32
(m, 1H, ArAH), 7.45 (q, 3H, J= 8.0 Hz, ArAH), 7.49 (t,
5H, J = 8.0 Hz ArAH), 7.46–7.48 (t, 5H, J = 8.0 Hz,
ArAH), 7.50–7.59 (q, 4H, J = 8.0 Hz, ArAH). ESI-MS (m/z)
calcd. is 463.5, found 464.5 [M +H]+; anal. calcd. for
C27H21N5OS (463.55): C 69.96, H 4.57, N 15.11; found: C
69.93, H 4.56, N 15.14.
2.6.15. 7-Methyl-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo
[3,4b][1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one
(4o)
White Solid Crystal; IR (KBr, cm1): 3009 (Ar CAH str), 2885
(Aliphatic CAH str), 1706 (C‚O str), 1606 (C‚N str), 1558
(C‚C str), 1305 (Ar CAN str), 664 (CASAC); 1H NMR
(CDCl3, 300 MHz): d (ppm): 2.43 (s, 3H, CH3), 4.53 (s, 2H,
SACH2A), 5.99 (s, 2H, CH2), 7.18 (s, 1H, CH‚), 7.41–7.44
(m, 2H, ArAH), 7.46 (t, 4H, J= 8.0 Hz, ArAH), 7.49 (q,
2H, J = 2.5 Hz, ArAH), 7.64–7.65 (m, 2H, ArAH), 7.75 (q,
2H, J = 8.5 Hz, ArAH), 8.18 (d, 1H, J = 8.0 Hz, ArAH).
ESI-MS (m/z) calcd. is 463.5, found 464.7 [M + H]+; anal.
calcd. for C27H21N5OS (463.55): C 69.96, H 4.57, N 15.11;
found: C 69.95, H 4.59, N 15.14.
2.6.16. 6-Methyl-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo
[3,4b][1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one
(4p)
White Solid Crystal; IR (KBr, cm1): 3004 (Ar CAH str), 2898
(Aliphatic CAH str),1705 (C‚O str), 1603 (C‚N str), 1559Please cite this article in press as: Ghosh, S. et al., Synthesis, characterization and ant
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(CDCl3, 300 MHz): 2.46 (s, 3H, CH3), 4.51 (s, 2H,
SACH2A), 5.98 (s, 2H, CH2), 6.45 (d, 1H, J = 8.5 Hz,
ArAH), 6.78 (s, 1H, CH‚), 7.43–7.45 (m, 3H, ArAH), 7.46
(t, 4H, J = 8.0 Hz, ArAH), 7.74 (q, 4H, J = 8.0 Hz, ArAH),
8.16 (m, 1H, ArAH). ESI-MS (m/z) calcd. is 463.5, found
464.6 [M + H]+; anal. calcd. for C27H21N5OS (463.55): C
69.96, H 4.57, N 15.11; found: C 69.98, H 4.53, N 15.15.
2.6.17. 8-Methoxy-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo
[3,4b][1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one
(4q)
White needle Crystal; IR (KBr, cm1): 3012 (Ar CAH str),
2870 (Aliphatic CAH str), 1708 (C‚O str), 1608 (C‚N str),
1566 (C‚C str), 1302 (Ar CAN str), 680 (CASAC); 1H
NMR (CDCl3, 300 MHz): d (ppm): 4.09 (s, 3H,OCH3), 4.50
(s, 2H, SACH2A), 5.98 (s, 2H, CH2), 6.78 (s, 1H, CH‚),
7.09 (q, 1H, J= 7.5 Hz, ArAH), 7.41 (m, 3H, ArAH), 7.46
(t, 5H, J = 8.0 Hz, ArAH), 7.73 (q, 4H, J = 8.0 Hz, ArAH).
ESI-MS (m/z) calcd. is 479.5, found 480.6 [M + H]+; anal.
calcd. for C27H21N5O2S (479.55): C 67.62, H 4.41, N 14.60;
found: C 67.62, H 4.46, N 14.68.
2.6.18. 7-Methoxy-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo
[3,4b][1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one
(4r)
White needle Crystal; IR (KBr, cm1): 3013 (Ar CAH str),
2890 (Aliphatic CAH str), 1703 (C‚O str), 1607 (C‚N str),
1565 (C‚C str), 1309 (Ar CAN str), 682 (CASAC); 1H
NMR (CDCl3, 300 MHz): 3.86 (s, 3H, OCH3), 4.51 (s, 2H,
SACH2A), 5.98 (s, 2H, CH2), 7.04 (d,2H,
J = 8.0 Hz,ArAH), 7.18 (s, 1H, CH‚), 7.41 (m, 2H,
ArAH), 7.46 (t, 4H, J = 8.0 Hz ArAH), 7.73 (q, 4H,
J= 8.0 Hz, ArAH), 8.35 (d, 1H, J= 8.0 Hz, ArAH). ESI-
MS (m/z) calcd. is 479.5, found 480.6 [M + H]+; anal. calcd.
for C27H21N5O2S (479.55): C 67.62, H 4.41, N 14.60; found:
C 67.64, H 4.45, N 14.58.
2.6.19. 6-Methoxy-4-phenyl-1({6-phenyl-7H-[1,2,4]triazolo
[3,4b][1,3,4]thiadiazin-3-yl}methyl)-1,2-dihydroquinolin-2-one
(4s)
White needle Crystal; IR (KBr, cm1): 3014 (Ar CAH str),
2875 (Aliphatic CAH str), 1707 (C‚O str), 1624 (C‚N str),
1563 (C‚C str), 1332 (Ar CAN str), 681 (CASAC); 1H
NMR (CDCl3, 300 MHz): d (ppm): 3.82 (s, 3H, OCH3), 4.51
(s, 2H, SACH2A), 5.98 (s, 2H, CH2), 6.79 (s, 1H,
CH‚),7.02 (q, 1H, J = 8.0 Hz, ArAH), 7.46 (m, 2H,
ArAH),7.48 (t, 6H, J = 8.0 Hz, ArAH), 7.68–7.69 (d, 3H,
J= 8.0 Hz, ArAH), 7.89 (d, 1H, J= 8.0 Hz, ArAH). ESI-
MS (m/z) calcd. is 479.5, found 480.4 [M + H]+; anal. calcd.
for C27H21N5O2S (479.55): C 67.62, H 4.41, N 14.60; found:
C 67.61, H 4.45, N 14.56.
2.6.20. 6,7,8-Trimethoxy-4-phenyl-1-({6-phenyl-7H-[1,2,4]
triazolo[3,4-b][1,3,4]thiadiazin-3-yl}methyl)-1,2-
dihydroquinolin-2-one (4t)
White needle Crystal; IR (KBr, cm1): 3023 (Ar CAH str),
2901 (Aliphatic CAH str),1706 (C‚O str), 1620 (C‚N str),
1564 (C‚C str), 1330 (Ar CAN str), 683 (CASAC); 1H
NMR (CDCl3, 300 MHz): d (ppm): 3.84 (s, 9H, 3xOCH3),
4.51 (s, 2H, SACH2A), 5.98 (s, 2H, CH2), 6.85 (s, 1H,imicrobial evaluation of some novel 1,2,4-triazolo [3,4-b][1,3,4]thiadiazine bear-
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Table 1 Physical and analytical data of synthesized compounds (4a–4t).
Comp. R Molecular formula m.p. (C) Yield Analysis of C, H, N (%), (cal./found)
C H N
4a H C26H19N5OS 202–203 69 69.47(69.43) 4.26(4.20) 15.58(15.53)
4b 2-Br C26H18BrN5OS 194–195 61 59.10(59.09) 3.43(3.48) 13.25(13.28)
4c 3-Br C26H18BrN5OS 180–181 69 59.10(59.12) 3.43(3.44) 13.25(13.19)
4d 4-Br C26H18BrN5OS 185–186 67 59.10(59.13) 3.43(3.39) 13.25(13.28)
4e 2-Cl C26H18ClN5OS 160–161 62 64.52(64.51) 3.75(3.77) 14.47(14.43)
4f 3-Cl C26H18ClN5OS 175–176 60 64.52(64.50) 3.75(3.71) 14.47(14.42)
4g 4-Cl C26H18ClN5OS 150–152 65 64.52(64.55) 3.75(3.79) 14.47(14.45)
4h 2-F C26H18FN5OS 140–142 59 66.79(66.73) 3.88(3.85) 14.98(14.99)
4i 3-F C26H18FN5OS 130–131 68 66.79(66.73) 3.88(3.84) 14.98(14.96)
4j 4-F C26H18FN5OS 115–116 60 66.79(66.77) 3.88(3.84) 14.98(14.99)
4k 2-NO2 C26H18N6O3S 146–147 72 63.15(63.19) 3.67(3.63) 16.99(16.98)
4l 3-NO2 C26H18N6O3S 155–156 76 63.15(63.12) 3.67(3.65) 16.99(16.95)
4m 4-NO2 C26H18N6O3S 165–166 75 63.15(63.10) 3.67(3.69) 16.99(16.95)
4n 2-CH3 C27H21N5OS 123–124 62 69.96(69.93) 4.57(4.56) 15.11(15.14)
4o 3-CH3 C27H21N5OS 132–133 59 69.96(69.95) 4.57(4.59) 15.11(15.14)
4p 4-CH3 C27H21N5OS 110–112 63 69.96(69.98) 4.57(4.53) 15.11(15.15)
4q 2-OCH3 C27H21N5O2S 210–211 56 67.62(67.62) 4.41(4.46) 14.60(14.68)
4r 3-OCH3 C27H21N5O2S 230–231 57 67.62(67.64) 4.41(4.45) 14.60(14.58)
4s 4-OCH3 C27H21N5O2S 225–226 62 67.62(67.61) 4.41(4.45) 14.60(14.56)
4t 3,4,5-t-OCH3 C29H25N5O4S 215–217 51 64.55(64.54) 4.67(4.63) 12.98(12.95)
6 S. Ghosh et al.CH‚), 7.45(d, 2H, J= 8.5 Hz, ArAH), 7.48(m,5H, ArAH),
7.74 (q, 4H, ArAH). ESI-MS (m/z) calcd. is 539.6, found
540.7 [M +H]+; anal. calcd. for C29H25N5O4S (539.60): C
64.55, H 4.67, N 12.98; found: C 64.54, H 4.63, N 12.95.
2.7. In-vitro antimicrobial assay/studies
2.7.1. Minimal Inhibitory Concentrations
Minimal Inhibitory Concentrations (MICs, lg/mL) were deter-
mined on different microbes using BrothMicro Dilution proce-
dure according to the recommendations of National
Committees for Clinical Laboratory Standards (NCCLS)
(Barry, 1991; CLSI Document, 2006; NCCLS Document,
2002). MIC was deﬁned as the lowest conc. of compound that
inhibited visible growth of microbes after incubation at 35 C
for 24 h. for bacteria and 48 h for fungi. Strains of gram ve
bacteria Pseudomonas aeruginosa (MCCB 0035), Escherichia
coli (ATCC8739) and gram+ve bacteriaStaphylococcus aureus
(ATCC 29213) and fungal strains Aspergillus fumigatus (NCIM
2081),Aspergillus niger (NCIM 2191),Candida albicans (NCIM
2087) were used for testing antibacterial and antifungal activi-
ties. Bacterial strains were grown in Mueller–Hinton Broth
and fungal strains were grown in Sabouraud Liquid medium.
The inoculum densities of 5 · 105 CFU/mL for bacteria and
0.5–2.5 · 103 CFU/mL for fungi were prepared. Ampicillin
Anhydride and ﬂuconazole were used as standard antibiotic
powder. The synthesized compounds were dissolved in DMSO
and further dilutions were prepared in sterile distilled water of
various concentrations by twofold serial dilution method to
obtain the required concentration 512, 256, 128, 64, 32, 16, 8,
4, 2, 1, 0.5, 0.25 lg/mL. Ampicillin anhydride and ﬂuconazole
were diluted in sterile distilled water. Twofold dilutions of the
compound and standards were prepared as 512–0.5 lg/mL
and 64–0.25 lg/mL concentrations respectively. After dilution
was completed, microbe suspensions were inoculated into each
well of row. MIC values were given as lg/mL. The turbidityPlease cite this article in press as: Ghosh, S. et al., Synthesis, characterization and an
ing substituted phenylquinolin-2-one moiety. Arabian Journal of Chemistry (2015),was monitored visually and spectrophotometrically and the
lowest concentration, at which no growth was seen, recorded
and considered as MIC of that particular compound. The
MIC of the synthesized compounds and standard drug has been
summarized in Table 2.
2.7.2. Agar Disk Diffusion
Agar Disk Diffusion testing technique was used as per CLSI
guidelines for evaluating antimicrobial potentials of synthe-
sized derivatives with suitable modiﬁcation. Mueller–Hinton
Agar (MHA) petri plates was prepared, standardized and then
inoculated with standardized test organism suspension. Stock
solution of synthesized compounds was prepared in DMSO
and further diluted with distilled water to get concentration
of test compounds 100 lg/ml, ampicillin (100 lg/ml) and
Clotrimazole (100 lg/ml). Disk of 8 mm diameter was pre-
pared from Whatman ﬁlter paper and sterilized by keeping
in hot air oven at 140 C for 1 h. Further the standard and test
solution were added to each disk (100 lg/8 mm disk) and then
with the help of sterile forceps placed on agar plates one at a
time. In a plate three disks were applied by triplicate manner
and it was ensured that disk made complete contact with agar
layer. Bottom of the agar plates was labeled and incubated at
temperature 35 C for 24 h and 48 h for bacterial and fungal
strains in BOD incubator. Measurement of zone of inhibition
produced by test compounds and standard drug against micro-
bial growth was done using a scale. Final data of zone of inhi-
bition obtained by different test compounds as compared with
that of standard have been enumerated in (Table 3).
3. Results and discussion
3.1. Chemistry
In the present work twenty derivatives of phenylquinoline-1,
2,4-triazolothiadiazines were synthesized. The structures oftimicrobial evaluation of some novel 1,2,4-triazolo [3,4-b][1,3,4]thiadiazine bear-
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Table 2 Minimum Inhibitory Concentration (MIC) in lg/mL of 1,2,4-triazolo thiadiazines (4a–4t)a,b against Bacterial and Fungal
strains.
Comp. code R Bacterial strains Fungal strains
EC PA SA AF AN CA
4a H 256 128 256 128 256 64
4b 2-Br 64 128 64 128 64 32
4c 3-Br 64 32 64 64 32 8
4d 4-Br 2 4 1 32 4 2
4e 2-Cl 256 256 128 >256 32 16
4f 3-Cl 128 128 64 128 16 16
4g 4-Cl 2 4 2 8 2 1
4h 2-F 128 128 64 64 32 8
4i 3-F 64 64 32 32 16 4
4j 4-F 8 8 2 4 4 2
4k 2-NO2 256 256 128 128 128 64
4l 3-NO2 128 256 64 128 32 16
4m 4-NO2 32 64 16 32 16 32
4n 2-CH3 >256 256 >256 >256 >256 128
4o 3-CH3 256 >256 >256 128 >256 256
4p 4-CH3 >256 128 128 128 256 128
4q 2-OCH3 128 64 32 64 32 16
4r 3-OCH3 64 32 16 32 16 32
4s 4-OCH3 64 128 64 128 64 32
4t 3,4,5-t-OCH3 64 128 64 64 32 16
AA Stand. drug 1 4 2 – – –
CL Stand. drug – – – 16 4 1
a Minimum inhibitory concentration was determined by micro-broth dilution method.
b E. coli, Escherichia coli ATCC 8739; P. aeruginosa, Pseudomonas aeruginosaMCCB 0035; S. aureus, Staphylococcus aureus ATCC 29213; A.
fumigatus, Aspergillus fumigatus NCIM 2081; A. niger, Aspergillus niger NCIM 2191; C. albicans, Candida albicans NCIM 2087.
Novel 1,2,4-triazolo[3,4-b][1,3,4]thiadiazine bearing substituted phenylquinolin-2-one moiety 7the synthesized compounds were established by spectral data.
According to IR spectroscopic data compounds (4a–4t)
showed peaks at 1306–1330 cm1, 650–682 cm1 due to -
N‚C and CASAC stretching vibrations respectively and no
absorption peaks at 3140–3280 cm1, 3050–3090 cm1 due to
-NH2 and -SH groups respectively indicated smooth cycliza-
tion of triazoles leading to the formation of thiadiazine ring.
Further, 1H NMR spectra of the synthesized compounds
were conﬁrmed by the appearance of SACH2 proton of
1,3,4-thiadiazine ring at 4.40–4.54 ppm and ACH2 proton at
5.97–6.20 ppm as broad singlet. All other aromatic protons
were observed at expected region. Mass spectra (ESI-MS) of
all the synthesized compounds showed molecular ion
[M+ H]+ peak in agreement with their molecular formula.
Physical and elemental analyses are listed in Table 1.
3.2. In-vitro antimicrobial assay/studies
3.2.1. Antibacterial activity
All the synthesized derivatives (4a–4t) were tested for their
in vitro antimicrobial activity against gram positive (S. aureus)
and gram negative (E. coli, P. aeruginosa) bacteria and results
have been presented in Tables 2 and 3. The resultant MIC value
of synthesized compounds was found in good agreement with
the results of zone of inhibition. Compounds 4d, 4g and 4j hav-
ing substitution at sixth position of phenyl quinolone ring
showed highest activity against all studied bacterial strains.
Highest activity was shown by compound 4d at MIC value
1 lg/mL against S. aureus, 2 lg/mL against E. Coli and 4
lg/mL P. aeruginosa. Other derivatives 4c, 4f, and 4i showed
comparable activity as compared with standard drug as thesePlease cite this article in press as: Ghosh, S. et al., Synthesis, characterization and ant
ing substituted phenylquinolin-2-one moiety. Arabian Journal of Chemistry (2015),had substitution by halogen atoms at seventh position of core
pharmacophore phenylquinoline ring. Compounds 4b, 4e, 4h,
4m and 4r also possessed some activity against tested bacterial
strains. Further replacement of halogen groups with methyl,
nitro, methoxy and tri-methoxy groups reduced antibacterial
potentials and compounds 4a, 4k, 4l, 4n, 4o, 4p, 4q, 4s and 4t
showed least activity as revealed fromMIC study from Table 2.
3.2.2. Antifungal activity
Compounds 4d, 4g and 4j showed highest activity against
tested fungal strains in comparison with clotrimazole. Both
MIC and Zone of Inhibition data from Tables 2 and 3 reveal
that halogen substitution at sixth position of phenylquinoline
ring. Compounds 4d and 4j showed nearly equipotent activity
as compared with standard drug at MIC concentration of 2
lg/mL and 4 lg/mL against A. niger and C. albicans whereas
compound 4g was the most potent at 1 lg/mL concentration
against C. albicans. Compounds 4b, 4c, 4e, 4f, 4h and 4i
showed moderate activity as hydrogen was substituted with
bromo, chloro and ﬂuro atoms at seventh and eighth position
of phenylquinoline ring. Antifungal activity further decreased
in compounds 4k, 4l, 4m, 4o, 4p, 4q, 4r and 4s having methyl,
nitro and methoxy groups at various position of phenylquino-
line ring. Least activity was seen in 4a and 4n against all stud-
ied fungal strains.
3.2.3. Structure activity relationship of antimicrobial study
MIC and Zone of Inhibition data showed and clariﬁed
Structure–activity relationship analysis of ﬁnal synthesized
derivatives. The study suggested that compounds having sub-
stitution on sixth, seventh and eight position ofimicrobial evaluation of some novel 1,2,4-triazolo [3,4-b][1,3,4]thiadiazine bear-
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Table 3 Zone of inhibition of 1,2,4-triazolo thiadiazines
(4a–4t)a,b against Bacterial and Fungal strains at concentration
of 100 lg/8 mm disk compared with broad spectrum antibac-
terial standard drug Ampicillin (AA) and Clotrimazole
(CL) 100 lg/8 mm disk.
Comp. code R Diameter of growth inhibition zone*
(mm)
EC PA SA AN CA
4a H 10 12 13 10 11
4b 2-Br 13 15 16 13 14
4c 3-Br 14 16 17 15 16
4d 4-Br 16 17 19 18 20
4e 2-Cl 12 13 15 17 18
4f 3-Cl 15 14 17 17 18
4g 4-Cl 16 17 19 20 23
4h 2-F 14 15 17 16 19
4i 3-F 12 15 16 18 20
4j 4-F 15 16 18 20 22
4k 2-NO2 12 15 16 16 17
4l 3-NO2 14 16 17 17 19
4m 4-NO2 12 14 15 15 16
4n 2-CH3 07 09 10 07 09
4o 3-CH3 07 08 11 09 10
4p 4-CH3 05 06 08 08 11
4q 2-OCH3 10 11 12 13 14
4r 3-OCH3 11 09 10 12 15
4s 4-OCH3 12 10 08 10 12
4t 3,4,5-t-OCH3 13 15 16 15 16
AA Stand. drug 18 17 21 – –
CL Stand. drug – – – 22 24
* Average of triplicate.
a Zone of inhibition of compounds was determined by
micro-broth dilution method.
b Ec: Escherichia coli; Pa: Pseudomonas aeruginosa; Sa:
Staphylococcus aureus; An: Aspergillus niger; Ca: Candida albicans;
AA: Ampicillin anhydride; CL: Clotrimazole.
8 S. Ghosh et al.phenylaquinoline ring by halogen atom possessed good activ-
ity. Specially having substitution at sixth position by halogen
group, compounds 4d, 4g and 4j emerged to be most useful
as they were having highest activity against both studied fungal
and bacterial strains, whereas substitution by electron donat-
ing groups, like compounds 4k, 4l, 4m, 4n, 4o, 4p, 4q, 4r, 4s
and 4t having methyl, nitro, methoxy and trimethoxy groups
was not as effective as halogen substituents.
4. Conclusion
In this study we have successfully synthesized and reported
synthesis of novel 1,2,4-triazolo[3,4-b][1,3,4]thiadiazine bear-
ing substituted phenylquinolin-2-one hybrids. This study
showed some 1,2,4-triazolo thiadiazines derivatives bearing
phenyl quinoline moiety possessed moderate to good antibac-
terial and antifungal activities. The antimicrobial study sug-
gested that compounds (4a–4t) by halogen substitution on
sixth position of phenylquinoline ring (4d, 4g and 4j) showed
highest activity against all studied microbial strains. Other
compounds also possessed some activity but failed to attract
more attention in comparison with standard drugs. The
authors are working further to optimize compounds with good
activity and ﬁndings will be reported in further publications.Please cite this article in press as: Ghosh, S. et al., Synthesis, characterization and an
ing substituted phenylquinolin-2-one moiety. Arabian Journal of Chemistry (2015),Acknowledgments
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